Abstract | BACKGROUND: AIMS: To assess the efficacy of methotrexate for psoriasiform lesions associated with anti-TNF therapy refractory to topical therapy in IBD patients. METHODS: The charts of eight patients from the Nancy IBD cohort who developed psoriasiform lesions on anti-TNF therapy were reviewed. Clinical response was defined as a decrease of more than 50% in the lesions covering surface. All patients were followed up by the same experienced dermatologist. RESULTS: Eight women (seven Crohn's disease) were followed up for a median duration of 29 months (range, 20-45). Of the eight patients receiving methotrexate, three were primary responders without discontinuation of anti-TNF agents. Only one patient had a sustained response at final follow-up and was able to continue both methotrexate and anti-TNF therapy. Of the two other primary responders, one patient had to discontinue anti-TNF because of severe psoriasiform lesions, whereas the other one continued anti-TNF therapy despite persistent skin lesions at final follow-up. Among the five primary nonresponders, four patients had to stop anti-TNF treatment due to disabling skin lesions. CONCLUSION:
Methotrexate does not appear effective in treating psoriasiform lesions associated with anti-TNF therapy refractory to topical therapy in IBD.
|
Authors | A Buisson, J-F Cuny, A Barbaud, J-L Schmutz, M-A Bigard, J-L Guéant, L Peyrin-Biroulet |
Journal | Alimentary pharmacology & therapeutics
(Aliment Pharmacol Ther)
Vol. 35
Issue 10
Pg. 1175-80
(May 2012)
ISSN: 1365-2036 [Electronic] England |
PMID | 22469155
(Publication Type: Journal Article)
|
Copyright | © 2012 Blackwell Publishing Ltd. |
Chemical References |
- Anti-Inflammatory Agents
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Humanized
- Dermatologic Agents
- Tumor Necrosis Factor-alpha
- Infliximab
- Adalimumab
- Methotrexate
|
Topics |
- Adalimumab
- Adult
- Anti-Inflammatory Agents
(adverse effects)
- Antibodies, Monoclonal
(adverse effects)
- Antibodies, Monoclonal, Humanized
(adverse effects)
- Dermatologic Agents
(therapeutic use)
- Female
- Humans
- Inflammatory Bowel Diseases
(drug therapy)
- Infliximab
- Methotrexate
(therapeutic use)
- Middle Aged
- Psoriasis
(chemically induced, drug therapy)
- Retrospective Studies
- Time Factors
- Treatment Outcome
- Tumor Necrosis Factor-alpha
(antagonists & inhibitors)
- Young Adult
|